Open AccessTreatment of Philadelphia1 Leukemia in Severe Combined Immunodeficient Mice by Combination of Cyclophosphamide and bcr/abl Antisense Oligodeoxynucleotides
Author(s) -
T Skórski,
Malgorzata Nieborowska-Skorska,
Paweł Włodarski,
Danilo Perrotti,
Mirosław Majewski,
Renato V. Iozzo,
Bruno Calabretta,
Grażyna Hoser,
J Kawiak,
Lasse Engbo Christensen
Publication year - 1997
Publication title -
jnci journal of the national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.797
H-Index - 356
eISSN - 1460-2105
pISSN - 0027-8874
DOI - 10.1093/jnci/89.2.124
Subject(s) - chronic myelogenous leukemia , breakpoint cluster region , leukemia , cancer research , abl , biology , cyclophosphamide , immunology , microbiology and biotechnology , chemotherapy , receptor , signal transduction , tyrosine kinase , biochemistry , genetics
Philadelphia cells are human chronic myelogenous leukemia (CML) cells that contain the BCR/ABL oncogene (a fusion of the BCR and ABL genes). Selective eradication of these cells in vitro can be achieved by combined treatment with antisense phosphorothioate oligodeoxynucleotides ([S]ODNs) specifically targeted to this oncogene (bcr/abl [S]ODNs) and a suboptimal (for use as a single agent) dose of mafosfamide (the in vitro active form of cyclophosphamide).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom